Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Discontinues Two Phase III Primary Care Projects

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer is halting development of treatments for generalized anxiety disorder and fibromyalgia.
Advertisement

Related Content

Comparative Evidence Needs Earlier Consideration In Drug Development Process – Novartis Exec
Filing Timeline Unclear After Sutent Trial In Rare Pancreatic Cancer Stops Early
Filing Timeline Unclear After Sutent Trial In Rare Pancreatic Cancer Stops Early
Fibromyalgia Market Snapshot: Forest Delays Savella Launch
Fibromyalgia Market Snapshot: Forest Delays Savella Launch
Pfizer’s Tanezumab For Pain Turns Heads At Rheumatology Meeting
Pfizer Restructures For A More Flexible Future
Pfizer Restructures For A More Flexible Future
Pfizer’s Lyrica Is First Drug Approved For Fibromyalgia

Topics

Advertisement
UsernamePublicRestriction

Register

PS069041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel